CURX

Curanex Pharmaceuticals Inc CURX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$89.0K total
CITADEL ADVISORS LLC
$25.3K+88.4%
Virtu Financial LLC
$14.0KNew
RENAISSANCE TECHNOLOGIES LLC
$13.8KNew
GEODE CAPITAL MANAGEMENT, LLC
$10.2K-65.5%
JANE STREET GROUP, LLC
$8.3KNew
TWO SIGMA INVESTMENTS, LP
$7.3K+35.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$3.9KNew
Ground Swell Capital, LLC
$3.4KNew
CITIGROUP INC
$2.4K-53.7%
UBS Group AG
$400-81.2%
Tower Research Capital LLC (TRC)
$265New
See all 11 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CURX

Earnings Per Share

13fpro.ai/company/CURX

Loading ratio trend…

About Curanex Pharmaceuticals Inc (CURX): stock profile, AI score and financials

Curanex Pharmaceuticals Inc (CURX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CURX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of CURX by reported 13-F value include CITADEL ADVISORS, Virtu Financial, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CURX trades on the Nasdaq exchange and files with the SEC under CIK 2025942. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CURX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Curanex Pharmaceuticals Inc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2025942 →